M. Snee

4.4k citations

48 papers · 2.8k · 3 hit papers · h-index 18

Impact in

Pulmonary and Respiratory Medicine top 1%
- Occupational and environmental lung diseases
- Lung Cancer Diagnosis and Treatment
- Pleural and Pulmonary Diseases
- Lung Cancer Treatments and Mutations
- Brain Metastases and Treatment
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
Oncology top 2%
- Lung Cancer Research Studies

Papers in

Pulmonary and Respiratory Medicine 36
- Lung Cancer Diagnosis and Treatment 20
- Lung Cancer Treatments and Mutations 15
- Occupational and environmental lung diseases 10
- Pleural and Pulmonary Diseases 6
- Gastric Cancer Management and Outcomes 3
Oncology 14
- Lung Cancer Research Studies 11

Co-authors: Corinne Faivre‐Finn (17 shared papers)Suresh Senan (6 shared papers)M. Hatton (6 shared papers)Elaine M. Rankin (4 shared papers)Laurence Collette (4 shared papers)G. Kramer (4 shared papers)Pieter E. Postmus (3 shared papers)Ben J. Slotman (3 shared papers)
Journals: Journal of Thoracic Oncology (8 papers)Clinical Oncology (5 papers)Lung Cancer (5 papers)Journal of Clinical Oncology (4 papers)BMJ Open (4 papers)
Partner nations: United Kingdom United States Belgium

In The Last Decade

M. Snee

47 papers receiving 2.8k citations

M. Snee's Hit Papers

align trajectories log scale

Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study 2011 · 454 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2011 The Lancet Oncology
2010 Thorax
2007 New England Journal of Medicine

Peers

Countries citing papers authored by M. Snee

Since Specialization

Citations

This map shows the geographic impact of M. Snee's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Snee with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Snee more than expected).

Fields of papers citing papers by M. Snee

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Snee. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Snee. The network helps show where M. Snee may publish in the future.

Co-authors

The 25 scholars most cited alongside M. Snee, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with M. Snee Line = papers co-authored together M. Snee links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 48 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Prophylactic Cranial Irradiation in Extensive Small-Cell Lung Cancer New England Journal of Medicine ·Ben J. Slotman, Corinne Faivre‐Finn, G. Kramer, Elaine M. Rankin, M. Snee, M. Hatton, Pieter E. Postmus, Laurence Collette, E. Musat, Suresh Senan Hit paper breakdown →	2007	716
2	Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study The Lancet Oncology ·Tom Treasure, Loı̈c Lang-Lazdunski, David Waller, Judith M. Bliss, Carol Tan, James Entwisle, M. Snee, Mary Claire O’Brien, Gill Thomas, Suresh Senan, Kenneth J. O’Byrne, Lucy Kilburn, James Spicer, David Landau, John Edwards, Gill Coombes, Liz Darlison, Julian Peto Hit paper breakdown →	2011	454
3	Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial The Lancet Oncology ·Corinne Faivre‐Finn, M. Snee, Linda Ashcroft, W. Appel, Fabrice Barlési, Adityanarayan Bhatnagar, Andrea Bezjak, Felipe Cardenal, P. Fournel, Susan Harden, C. Le Péchoux, R. McMenemin, (unknown), Mary O’Brien, Jason Pantarotto, Veerle Surmont, Jan P. van Meerbeeck, Penella J. Woll, Paul Lorigan, Fiona Blackhall	2017	366
4	Guidelines on the radical management of patients with lung cancer Thorax ·Eric Lim, David Baldwin, M. Beckles, John P. Duffy, James Entwisle, Corinne Faivre‐Finn, Keith M. Kerr, Alistair Macfie, J. McGuigan, Simon Padley, Sanjay Popat, N. Screaton, M. Snee, David Waller, Christopher Warburton, Thin Thin Win, (unknown) Hit paper breakdown →	2010	365
5	Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial The Lancet ·Martin F. Muers, Richard Stephens, P.M. Fisher, Liz Darlison, C M B Higgs, Erica Lowry, Andrew G. Nicholson, Mary O’Brien, Michael Peake, Robin Rudd, M. Snee, Jeremy Steele, D.J. Girling, Matthew Nankivell, Cheryl Pugh, Mahesh Parmar	2008	178
6	Prophylactic Cranial Irradiation in Extensive Disease Small-Cell Lung Cancer: Short-Term Health-Related Quality of Life and Patient Reported Symptoms—Results of an International Phase III Randomized Controlled Trial by the EORTC Radiation Oncology and Lung Cancer Groups Journal of Clinical Oncology ·(unknown), Murielle Mauer, Andrew Bottomley, Corinne Faivre‐Finn, G. Kramer, Elaine M. Rankin, M. Snee, M. Hatton, Pieter E. Postmus, Laurence Collette, Suresh Senan	2008	165
7	SOCCAR: A randomised phase II trial comparing sequential versus concurrent chemotherapy and radical hypofractionated radiotherapy in patients with inoperable stage III Non-Small Cell Lung Cancer and good performance status European Journal of Cancer ·J. Maguire, Iftekhar Khan, R. McMenemin, N. O’Rourke, S.G. McNee, V. Kelly, C. Peedell, M. Snee	2014	95
8	The Mesothelioma and Radical Surgery Randomized Controlled Trial: The MARS Feasibility Study Journal of Thoracic Oncology ·Tom Treasure, David Waller, Carol Tan, James Entwisle, Mary Claire O’Brien, Kenneth J. O’Byrne, Gill Thomas, M. Snee, James Spicer, David Landau, Loı̈c Lang-Lazdunski, Judith M. Bliss, Clare Peckitt, Shaun Rogers, Erica Marriage, Gillian Coombes, Mark Webster-Smith, Julian Peto	2009	55
9	A phase III trial of docetaxel/carboplatin versus mitomycin C/ifosfamide/cisplatin (MIC) or mitomycin C/vinblastine/cisplatin (MVP) in patients with advanced non-small-cell lung cancer: a randomised multicentre trial of the British Thoracic Oncology Group (BTOG1) Annals of Oncology ·Richard Booton, Paul Lorigan, Heather Anderson, Sofia Baka, Linda Ashcroft, M. Nicolson, Mary Claire O’Brien, David J. Dunlop, Kenneth J. O’Byrne, V. Laurence, M. Snee, G. Dark, N. Thatcher	2006	53
10	Prophylactic Irradiation of Tracts in Patients With Malignant Pleural Mesothelioma: An Open-Label, Multicenter, Phase III Randomized Trial Journal of Clinical Oncology ·N. Bayman, W. Appel, Linda Ashcroft, David Baldwin, Andrew Bates, Liz Darlison, John Edwards, Veni Ezhil, David Gilligan, M. Hatton, A. Jegannathen, T. Mansy, Michael Peake, L. Pemberton, Robert C. Rintoul, M. Snee, W. David J. Ryder, Paul Taylor, Corinne Faivre‐Finn	2019	38
11	Protocol for the CONVERT trial—Concurrent ONce-daily VErsus twice-daily RadioTherapy: an international 2-arm randomised controlled trial of concurrent chemoradiotherapy comparing twice-daily and once-daily radiotherapy schedules in patients with limited stage small cell lung cancer (LS-SCLC) and good performance status BMJ Open ·Corinne Faivre‐Finn, S. Falk, Linda Ashcroft, M. Bewley, Paul Lorigan, Elena Wilson, N. Groom, M. Snee, P. Fournel, Felipe Cardenal, Andrea Bezjak, Fiona Blackhall	2016	30
12	Stereotactic Ablative Radiotherapy (SABR) in Patients with Medically Inoperable Peripheral Early Stage Lung Cancer: Outcomes for the First UK SABR Cohort Clinical Oncology ·Louise Murray, S. Ramasamy, J. Lilley, M. Snee, K. Clarke, Hima Bindu Musunuru, A. Needham, R. Turner, V. Sangha, Michael Flatley, K. Franks	2015	29
13	The SABRTooth feasibility trial protocol: a study to determine the feasibility and acceptability of conducting a phase III randomised controlled trial comparing stereotactic ablative radiotherapy (SABR) with surgery in patients with peripheral stage I non-small cell lung cancer (NSCLC) considered to be at higher risk of complications from surgical resection Pilot and Feasibility Studies ·M. Snee, Lucy McParland, Fiona Collinson, Catherine Lowe, Alina Striha, David Baldwin, Babu Naidu, David Sebag‐Montefiore, Walter M. Gregory, Janine Bestall, Jenny Hewison, Samantha Hinsley, K. Franks	2016	29
14	18F-Fludeoxyglucose PET/CT in SCLC: Analysis of the CONVERT Randomized Controlled Trial Journal of Thoracic Oncology ·Prakash Manoharan, Ahmed Salem, Hitesh Mistry, Michael Gornall, Susan Harden, P. J. Julyan, Imogen Locke, J. McAleese, R. McMenemin, N. Mohammed, M. Snee, S. D. Woods, Thomas Westwood, Corinne Faivre‐Finn	2019	22
15	CONVERT: An international randomised trial of concurrent chemo-radiotherapy (cCTRT) comparing twice-daily (BD) and once-daily (OD) radiotherapy schedules in patients with limited stage small cell lung cancer (LS-SCLC) and good performance status (PS). Journal of Clinical Oncology ·Corinne Faivre‐Finn, M. Snee, Linda Ashcroft, W. Appel, Fabrice Barlési, Adityanarayan Bhatnagar, Andrea Bezjak, Felipe Cardenal, P. Fournel, Susan Harden, C. Le Péchoux, R. McMenemin, N. Mohammed, Mary O’Brien, Jason Pantarotto, Veerle Surmont, Jan P. van Meerbeeck, Penella J. Woll, Paul Lorigan, Fiona Blackhall	2016	22
16	Treatment patterns and outcomes for patients with malignant pleural mesothelioma in England in 2013–2017: A nationwide CAS registry analysis from the I-O Optimise initiative Lung Cancer ·(unknown), M. Daumont, Laure Lacoin, John R. Penrod, Robert Carroll, Sudhir Venkatesan, Harveen Ubhi, Alan Calleja, M. Snee	2021	19
17	Stereotactic Ablative Body Radiotherapy for Lung Cancer Clinical Oncology ·K. Franks, Pooja Jain, M. Snee	2015	18
18	Occult Nodal Disease in Patients With Non–Small-Cell Lung Cancer Who are Suitable for Stereotactic Ablative Body Radiation Clinical Lung Cancer ·Jonathan Robson, Sriram Vaidyanathan, Leanne Cheyne, M. Snee, K. Franks, Matthew Callister	2014	18
19	Lung stereotactic ablative radiotherapy (SABR): dosimetric considerations for chest wall toxicity British Journal of Radiology ·Louise Murray, Ebru Karakaya, Samantha Hinsley, Mitchell Naisbitt, J. Lilley, M. Snee, K. Clarke, Hima Bindu Musunuru, Satiavani Ramasamy, R. Turner, K. Franks	2016	16
20	Surgery or radiotherapy for stage I lung cancer? An intention-to-treat analysis European Respiratory Journal ·Katie Spencer, Martyn Kennedy, Katie Lummis, Deborah Ellames, M. Snee, Alessandro Brunelli, K. Franks, Matthew Callister	2019	16

About M. Snee

M. Snee is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Radiation, Otorhinolaryngology and Epidemiology, having authored 48 papers that have together received 2.8k indexed citations. Recurring topics across this work include Lung Cancer Diagnosis and Treatment (20 papers), Lung Cancer Treatments and Mutations (15 papers), Lung Cancer Research Studies (11 papers), Occupational and environmental lung diseases (10 papers), Pleural and Pulmonary Diseases (6 papers), Advanced Radiotherapy Techniques (5 papers), Gastric Cancer Management and Outcomes (3 papers) and Head and Neck Cancer Studies (2 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (1.7k citations), Oncology (1.2k citations), Epidemiology (458 citations), Radiation (90 citations) and Radiology, Nuclear Medicine and Imaging (209 citations). M. Snee has collaborated with scholars based in United Kingdom, United States and Belgium. Frequent co-authors include Corinne Faivre‐Finn, Suresh Senan, M. Hatton, Elaine M. Rankin, Laurence Collette, G. Kramer, Pieter E. Postmus, Ben J. Slotman, E. Musat and David Waller. Their work appears in journals such as Journal of Thoracic Oncology, Clinical Oncology, Lung Cancer, Journal of Clinical Oncology and BMJ Open.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

M. Snee

Impact in

Papers in i

In The Last Decade

M. Snee

M. Snee's Hit Papers

Peers

Countries citing papers authored by M. Snee

Fields of papers citing papers by M. Snee

All Works

About M. Snee

Explore authors with similar magnitude of impact

Papers in